Related Experiment Video
Updated: Jul 7, 2026

Protocol to Create Chronic Wounds in Diabetic Mice
Published on: September 25, 2019
Chelidonium majus L.-containing gel may improve diabetic wound healing by modulating MMP-2, MMP-9, and collagen
Kaan Kaltalioğlu1, Elif Naz Gürsoy2, Kanuni Barbaros Balabanli2
1Programme of Occupational Health and Safety, Vocational School of Espiye, Giresun University, Giresun, Turkiye.
Background/Aim:
Delayed wound healing in diabetic patients is a significant complication that reduces quality of life, prompting the continuous investigation of new therapeutic agents. This study designed to explore the dose-dependent effects of different parts of Chelidonium majus L. (CM), a medicinal plant traditionally used for skin disorders, on diabetic skin wounds.
Materials And Methods:
In diabetic rats, full-thickness excisional wounds were formed. CM-containing gels (aerial parts at 3%, 6%, 9% and root at 0.5%, 1%, 1.5%) were developed and applied to the wounds. After the treatment period, the rats were sacrificed, and wound healing activity was assessed macroscopically, histopathologically, and biochemically.
Results:
The CM-containing gels (aerial parts or root) accelerated wound closure and increased collagen, glutathione (GSH), and ascorbic acid (AA) content. Additionally, these gels reduced oxidative stress markers, and interleukin-1β (IL-1β) and IL-13 levels, while modulating the activities of matrix metalloproteinase-2 (MMP-2) and MMP-9.
Conclusion:
CM accelerates the healing process by increasing antioxidant capacity and modulating MMP activity, and it may have dose-dependent effectiveness in diabetic wound management.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Diabetic Foot Ulcer
Diabetic Retinopathy

